OmniAb OABI

Matthew W. Foehr is President and Chief Executive Officer and a member of our board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., (Nasdaq: VKTX) a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020. Mr. Foehr received his BS degree in biology from Santa Clara University.

Charles S. Berkman has served as Chief Legal Officer and Secretary since November 2022. Previously, Mr. Berkman had served as a member of Legacy OmniAb's board of directors and as OmniAb's Secretary since December 2015 and as Legacy OmniAb's Chief Legal Officer since March 2022. Mr. Berkman had also served as Ligand's Senior Vice President, General Counsel and Secretary since January 2018 and prior to that as its Vice President, General Counsel and Secretary since April 2007. Mr. Berkman joined Ligand in November 2001 and served as Associate General Counsel and Chief Patent Counsel (and Secretary since March 2007). Prior to joining Ligand, Mr. Berkman was an attorney at the international law firm of Baker & McKenzie from November 2000 to November 2001. Before that he served as an attorney at the law firm of Lyon & Lyon from 1993 to November 2000, where he specialized in intellectual property law. Mr. Berkman earned a B.S. in chemistry from the University of Texas and a J.D. from the University of Texas School of Law.

Kurt A. Gustafson has served as our Executive Vice President, Finance and Chief Financial Officer since November 2022. Mr. Gustafson had served as Legacy OmniAb's Executive Vice President, Finance and Chief Financial Officer since March 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he held since June 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, most recently as Vice President, Finance. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the board of directors of Xencor, Inc. (Nasdaq: XNCR), a publicly traded biopharmaceutical company. Mr. Gustafson received a B.A. in accounting at North Park University and an M.B.A. from the University of California, Los Angeles.

Steve Crouse has over 20 years of experience in research and development, business development, and general management. Mr. Crouse has served as the Senior Vice President and General Manager of the Analytical Solutions Division at Bio-Techne Corporation, a public life sciences company, since March 2021, overseeing the company's ProteinSimple branded products and R&D Systems Immunoassays portfolio. Previously Mr. Crouse served as the Senior Director and General Manager of the Protein Detection and Quantification unit at Thermo Fisher Scientific Inc. from June 2018 to March 2021. Prior to that, Mr. Crouse served as Chief Operating Officer at Vortex Biosciences, Inc. and Senior Vice President of Sales and Marketing at Freeslate Inc., which was sold to Unchained Labs in 2016. He also held leadership roles at Bio-Rad Laboratories and Invitrogen Corporation. Mr. Crouse holds a B.S. in pharmacology from the University of California, Santa Barbara, an M.S. in biochemistry from Georgetown University, and an M.B.A. from the Marshall School of Business at the University of Southern California.

Philip J. Gotwals has 30 years of biopharmaceutical experience in R&D, business development, product development and therapeutic area strategy. He was Global Head of Business Development and Licensing at Novartis Institutes for BioMedical Research (NIBR) from November 2019 to October 2023, where he oversaw business development for all disease areas and technology platforms. Prior to that, Dr. Gotwals was Global Head, Search and Evaluation, Business Development and Licensing of NIBR from June 2017 to November 2019. Dr. Gotwals also served as Executive Director, Oncology/Immuno-Oncology Research at NIBR from September 2010 to June 2017, and previously as Executive Director and Franchise Head, Oncology from April 2009 to August 2010. Prior to NIBR, he was Vice President, Program Management at Altus Pharmaceuticals from 2006 to 2009, where he was responsible for product development and project management activities. Prior to Altus, he was with Biogen Idec from 1994 to 2006 in increasing roles of leadership, most recently as Senior Director, Department of Program and Alliance Management. Dr. Gotwals has served as a Partner at RedSky Partners, LLC, which provides advisory services to the biotechnology industry in the areas of corporate strategy and business development, since November 2023. Dr. Gotwals serves on the board of directors of Capricor Therapeutics, Inc. Dr. Gotwals has a B.A. in biology from Amherst College, holds a Ph.D. in genetics from the University of California at Berkeley, completed postdoctoral research at the Massachusetts Institute of Technology, business training at Harvard Business School and has published extensively in the area of integrin biology.

Steve Love has served as Chief Financial Officer of Sift Science, Inc., an AI platform-based company for identity-centric fraud prevention since April 2024. Prior to Sift, Mr. Love served as Chief Financial Officer at Heap Inc., a global SaaS product analytics company from September 2021 to December 2023. Prior to Heap, Mr. Love served as Chief Financial Officer at Juniper Square Inc. from 2020 to 2021 and, before that, served as Chief Financial Officer at Dialpad, Inc. since 2016. Mr. Love has spent nearly 30 years in finance, leading the growth strategy and data-driven decision-making at Mblox Inc. (acquired by CLX in July 2016), Evolv Inc. (acquired by Cornerstone OnDemand in November 2014), Affymax, Inc., and Connetics Corporation, among others. He began his career at Ernst & Young LLP, supporting private and public biotechnology and software companies. Mr. Love holds a Masters in accounting and a B.S. in accounting from the University of Southern California and is a Certified Public Accountant in California (inactive).

John Higgins served as Chief Executive Officer at Ligand Pharmaceuticals Incorporated from January 2007 to December 2022. Prior to joining Ligand, Mr. Higgins served as Chief Financial Officer at Connetics Corporation (Connetics), a specialty pharmaceutical company, since 1997, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics until its acquisition by Stiefel Laboratories, Inc. in December 2006. Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX). Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves on the board, audit committee and nominations and governance committee of Bio-Techne Corporation (Nasdaq: TECH), a publicly-traded life sciences services company. Mr. Higgins has served as a director on numerous public and private companies. Mr. Higgins graduated Magna Cum Laude from Colgate University with an A.B. in economics.

Since June 2015, Dr. Bertozzi has served at Stanford University, where she is currently the Anne T. and Robert M. Bass Professor of Chemistry, a professor of Chemical and Systems Biology and Radiology and the Baker Family Director of Sarafan ChEM-H. Since 2000, Dr. Bertozzi has also served as an Investigator at the Howard Hughes Medical Institute and is the former Director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory. From 1996 to 2015, she was a professor of Chemistry and Molecular and Cell Biology at the University of California, Berkeley. Dr. Bertozzi currently serves on the boards of directors of Eli Lilly, Acepodia and Xaira Therapeutics, a privately held biotechnology company, and previously served as a member of the board of directors of Alnylam Pharmaceuticals from 2023 to 2025. Dr. Bertozzi was awarded the 2022 Nobel Prize in Chemistry for the development of click chemistry and bioorthogonal chemistry, and was also awarded the 2022 Wolf Prize in Chemistry. In addition to her academic work, Dr. Bertozzi has founded multiple biotechnology start-ups based around her research. Dr. Bertozzi holds an undergraduate degree in chemistry from Harvard University and a Ph.D. in chemistry from the University of California, Berkeley.

Jennifer Cochran, Ph.D. has served in numerous roles at Stanford University since 2005, where she is currently the Senior Associate Vice Provost of Research, Addie and Al Macovski Professor of Bioengineering. She is a founding member of the Stanford Department of Bioengineering, and served as its Chair from 2017 to 2022. Dr. Cochran has served as Chief Scientific Advisor to Red Tree Venture Capital, a life-sciences-focused investment fund, since she co-founded it in August 2020. Dr. Cochran was also the Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October 2015 to April 2020. Prior to Stanford, she held several research positions at the Massachusetts Institute of Technology, most recently as a Postdoctoral Fellow. Dr. Cochran currently serves on the boards of directors of privately-held biotechnology companies Revel Pharmaceuticals, Excellergy Therapeutics, Biograph 55, Rondo Therapeutics, and Tachyon Therapeutics, and is a board observer at Acrigen Biosciences. She has also served on the boards of directors of privately-held biotechnology companies she founded including Combangio, Inc. (acquired by Kala Bio in 2021), as well as xCella Biosciences until its acquisition by Ligand Pharmaceuticals in 2020. Dr. Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry from the Massachusetts Institute of Technology.

Effective July 13, 2026, Amechi Nwachuku was appointed as the Chief Operating Officer of OmniAb, Inc. Mr. Nwachuku, is a global life sciences executive with more than two decades of leadership experience spanning life sciences tools, biotechnology, diagnostics, pharmaceuticals, medical devices, and consumer health. Most recently, from May 2024 to April 2025, Mr. Nwachuku served as Vice President, Global Commercial, Genetic Sciences at Thermo Fisher Scientific. From August 2021 to June 2023, he served as Senior Vice President, Global Commercial at SCIEX, a Danaher Corporation operating company and from January 2019 to August 2021, he served as Vice President, Commercial Management for Eastern Europe and the Middle East at Beckman Coulter Diagnostics, another Danaher operating company. From August 2016 to December 2018, Mr. Nwachuku served as Regional Vice President for the Johnson & Johnson Diabetes Care Companies. From 2006 to 2016, he held a series of leadership roles at Bayer. Mr. Nwachuku holds an M.B.A from the MIT Sloan School of Management and a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.